| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_921f5387a1e26c89900742b8c8c2c4dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f0752ae37470d38fb00b638f45de8f59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4a88a6356665a34c669d9a91be90548e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_730640d4245582eb94f517443a707e05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_65138353b56126bf632731ddcda55694
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_70ad05638661d1e2fea8abce68ccdea4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 |
| filingDate |
2007-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b678c8d4e8006c37df01ae7b6d7aff3c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e74844359fa2ea9b2ffa2595dce08f6e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6347163eef4028aaeb601a6d91e1ec1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4af50544d0e41aae965dcf8479fe39c2 |
| publicationDate |
2007-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2007088460-A2 |
| titleOfInvention |
Tgf-beta modulators and use thereof |
| abstract |
The present invention relates to molecules preferably of polypeptide nature with negative regulatory activity on the amount or activity of TGF-β through direct interaction with pro-TGF-β, and containing as active region a cysteine-rich polypeptide sequence defined as 'EMI domain', or its subfragments, wherein said 'EMI domain' has at least 25% sequence homology to the ID NO2 sequence for pharmaceutical use. Even more preferably said polypeptide sequence consists of the EMI domain of the following proteins: emilin-1, emilin-2 and/or multimerin-2 or their subfragments having a length of at least 6 amino acids, capable of inhibiting the conversion of pro-TGFβ to mature TGF β as anti-hypertensive drugs and polypeptides active on the cardiovascular system. The invention extends to the use of molecules which are known to negatively regulate TGF-β and to molecules which interfere with TGF-β binding to its receptors, or to inhibitors of TGF-β mRNA synthesis or TGF-β expression for the same therapeutic uses as anti-hypertensive drugs and polypeptides active on the cardiovascular system. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021228817-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3909600-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007088459-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007088459-A2 |
| priorityDate |
2006-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |